Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Cash: 2015-2024

Historic Change in Cash for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$37.6 million.

  • Intellia Therapeutics' Change in Cash rose 459.45% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 256.22%. This contributed to the annual value of -$37.6 million for FY2024, which is 87.27% up from last year.
  • Intellia Therapeutics' Change in Cash amounted to -$37.6 million in FY2024, which was up 87.27% from -$295.1 million recorded in FY2023.
  • Over the past 5 years, Intellia Therapeutics' Change in Cash peaked at $410.0 million during FY2022, and registered a low of -$295.1 million during FY2023.
  • Its 3-year average for Change in Cash is $25.8 million, with a median of -$37.6 million in 2024.
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Cash soared by 6,687.73% in 2020, and later slumped by 171.98% in 2023.
  • Intellia Therapeutics' Change in Cash (Yearly) stood at $107.4 million in 2020, then plummeted by 136.43% to -$39.1 million in 2021, then soared by 1,148.00% to $410.0 million in 2022, then plummeted by 171.98% to -$295.1 million in 2023, then skyrocketed by 87.27% to -$37.6 million in 2024.